

UNIVERSITY OF BIRMINGHAM

University of Birmingham
Research at Birmingham

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care

Roddy, Edward; Clarkson, Kris; Blagojevic-Bucknall, Milisa ; Mehta, Rajnikant ; Opong, Raymond; Avery, Anthony; Hay, Elaine; Heneghan, Carl; Hartshorne, Liz ; Hooper, Julie ; Hughes, Gemma; Jowett, Sue; Lewis, Martyn; Little, Paul; McCartney, Karen ; Mahtani, Kamal ; Nunan, David; Santer, Miriam ; Williams, Sam ; Mallen, Christian

DOI:

[10.1136/annrheumdis-2019-216154](https://doi.org/10.1136/annrheumdis-2019-216154)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Roddy, E, Clarkson, K, Blagojevic-Bucknall, M, Mehta, R, Opong, R, Avery, A, Hay, E, Heneghan, C, Hartshorne, L, Hooper, J, Hughes, G, Jowett, S, Lewis, M, Little, P, McCartney, K, Mahtani, K, Nunan, D, Santer, M, Williams, S & Mallen, C 2020, 'Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care', *Annals of the Rheumatic Diseases*, vol. 79, no. 2, pp. 276-284. <https://doi.org/10.1136/annrheumdis-2019-216154>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Roddy, E, Clarkson, K, Blagojevic-Bucknall, M, Mehta, R, Opong, R, Avery, A, Hay, E, Heneghan, C, Hartshorne, L, Hooper, J, Hughes, G, Jowett, S, Lewis, M, Little, P, McCartney, K, Mahtani, K, Nunan, D, Santer, M, Williams, S & Mallen, C (2019), 'An open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care', *Annals of the Rheumatic Diseases*, pp. 1-9. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. <https://doi.org/10.1136/annrheumdis-2019-216154>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 06. May. 2021

Supplementary Table 1: recruitment by region and GP practice

	Naproxen	Colchicine
Recruitment by region, n (%)		
Keele	55 (27.5%)	52 (26.1%)
Southampton	88 (44.0%)	101 (50.8%)
Oxford	41 (20.5%)	31 (15.6%)
Nottingham	16 (8.0%)	15 (7.5%)
Participants recruited per practice, median (IQR)*	2 (1-4)	2 (1-3)

*75/100 GP practices who agreed to take part recruited at least one participant. Numbers recruited per practice ranged from 1 (21 practices) to 41 for the best recruiting practice (skewed upwards); overall median of 3 (IQR 1-7). IQR, interquartile range

Supplementary table 2: per protocol analyses

	1		2		3	
	Mean difference (95% CI)	P value	Mean difference (95% CI)	P value	Mean difference (95% CI)	P value
Day 1	0.01 (-0.45 to 0.46)	0.97	-0.04 (-0.50 to 0.41)	0.85	-0.04 (-0.54 to 0.46)	0.88
Day 2	-0.43 (-0.88 to 0.02)	0.063	-0.47 (-0.92 to -0.02)	0.040	-0.57 (-1.07 to -0.07)	0.024
Day 3	-0.11 (-0.56 to 0.33)	0.62	-0.17 (-0.62 to 0.28)	0.47	-0.20 (-0.69 to 0.30)	0.44
Day 4	-0.11 (-0.56 to 0.34)	0.62	-0.19 (-0.64 to 0.26)	0.41	-0.23 (-0.72 to 0.27)	0.37
Day 5	-0.16 (-0.61 to 0.28)	0.47	-0.25 (-0.71 to 0.20)	0.27	-0.23 (-0.73 to 0.27)	0.36
Day 6	-0.18 (-0.63 to 0.26)	0.42	-0.31 (-0.77 to 0.14)	0.17	-0.22 (-0.72 to 0.27)	0.38
Day 7 [#]	-0.28 (-0.72 to 0.16)	0.22	-0.43 (-0.88 to 0.02)	0.061	-0.41 (-0.91 to 0.08)	0.10
Overall (Days 1-7)	-0.18 (-0.54 to 0.17)	0.32	-0.27 (-0.62 to 0.09)	0.14	-0.27 (-0.67 to 0.13)	0.18
Week 4	-0.24 (-0.68 to 0.20)	0.29	-0.48 (-0.94 to -0.03)	0.038	-0.57 (-1.07 to -0.07)	0.025

Definition of per-protocol analyses:-

1 = No treatment violation by medical record note reporting (no treatment crossover + no early cessation of treatment) {n (A/B) = 184/182; 1014 / 1054 repeat data across days 1-7}

2 = At least 1-day use of randomised treatment by self-report (in addition to 1 above) {n (A/B) = 149/155; 998 / 1032 repeat data across days 1-7}

3 = 7 days (4-7 days) use of randomised treatment naproxen (colchicine) by self-report (in addition to 1 above) {n (A/B) = 118/134; 807 / 890 repeat data across days 1-7}

Summary is inclusive of minimum data collection (for scores at day 7)

Supplementary table 3: Comparison of complete pain resolution over days 1-7 and at 4 weeks

	Naproxen	Colchicine	χ^2	P value
Day 1	2/160 (1.3%)	8/164 (4.9%)	3.6	0.10*
Day 2	11/161 (6.8%)	12/164 (7.3%)	0.03	0.87
Day 3	29/163 (17.8%)	29/166 (17.5%)	0.01	0.94
Day 4	56/158 (35.4%)	55/168 (32.7%)	0.27	0.61
Day 5	79/156 (50.6%)	72/159 (45.3%)	0.91	0.34
Day 6	95/157 (60.5%)	89/160 (55.6%)	0.78	0.38
Day 7	115/171 (67.3%)	116/173 (67.1%)	<0.01	0.97
Week 4	130/173 (75.1%)	130/177 (73.4%)	0.13	0.72

* Complete-case responders to all pain questions (diary days 1 through 7 and at 4 weeks).

Median = Day 5 for Naproxen; Median = Day 6 for Colchicine.

Interquartile range: Day 4, Week 4 [in both treatment groups].

P value by Mann-Whitney U test = 0.73.

Supplementary Table 4: Self-reported daily side-effects within the first week of follow-up – complete-case data

	Day1		Day2		Day3		Day4		Day5		Day6		Day7	
	N	C	N	C	N	C	N	C	N	C	N	C	N	C
	(n=160)	(n=164)	(n=161)	(n=164)	(n=163)	(n=166)	(n=160)	(n=168)	(n=160)	(n=162)	(n=158)	(n=162)	(n=172)*	(n=176)*
	NP	CC	NP	CC	NP	CC	NP	CC	NP	CC	NP	CC	NP	CC
Nausea	17 (10.6%)	15 (9.1%)	11 (6.8%)	16 (9.8%)	7 (4.3%)	17 (10.2%)	6 (3.8%)	11 (6.5%)	6 (3.8%)	6 (3.7%)	2 (1.3%)	6 (3.7%)	3 (1.7%)	5 (2.8%)
Vomiting	3 (1.9%)	1 (0.6%)	2 (1.2%)	1 (0.6%)	1 (0.6%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)
Nausea and/or vomiting	19 (11.9%)	16 (9.8%)	12 (7.5%)	17 (10.4%)	7 (4.3%)	18 (10.8%)	6 (3.8%)	11 (6.5%)	6 (3.8%)	6 (3.7%)	2 (1.3%)	7 (4.3%)	3 (1.7%)	5 (2.8%)
Dyspepsia	10 (6.3%)	13 (7.9%)	11 (6.8%)	11 (6.7%)	11 (6.7%)	14 (8.4%)	9 (5.6%)	11 (6.5%)	5 (3.1%)	7 (4.3%)	6 (3.8%)	6 (3.7%)	4 (2.3%)	6 (3.4%)
Abdominal pain	5 (3.1%)	7 (4.3%)	6 (3.7%)	8 (4.9%)	7 (4.3%)	8 (4.8%)	7 (4.4%)	8 (4.8%)	3 (1.9%)	9 (5.6%)	2 (1.3%)	6 (3.7%)	4 (2.3%)	6 (3.4%)
Headache	9 (5.6%)	16 (9.8%)	10 (6.2%)	12 (7.3%)	3 (1.8%)	13 (7.8%)	3 (1.9%)	13 (7.7%)	5 (3.1%)	10 (6.2%)	4 (2.5%)	5 (3.1%)	3 (1.7%)	4 (2.3%)
Constipation	8 (5.0%)	1 (0.6%)	15 (9.3%)	2 (1.2%)	16 (9.8%)	5 (3.0%)	8 (5.0%)	4 (2.4%)	6 (3.8%)	3 (1.9%)	6 (3.8%)	2 (1.2%)	5 (2.9%)	3 (1.7%)
Diarrhoea	7 (4.4%)	20 (12.2%)	7 (4.3%)	28 (17.1%)	12 (7.4%)	40 (24.1%)	10 (6.3%)	52 (31.0%)	3 (1.9%)	34 (21.0%)	7 (4.4%)	18 (11.1%)	5 (2.9%)	13 (7.4%)
Skin rash	2 (1.3%)	3 (1.8%)	2 (1.2%)	2 (1.2%)	0 (0.0%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	1 (0.6%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	0 (0.0%)	2 (1.1%)
Any side effect(s) [#]	54 (33.8%)	54 (32.9%)	50 (31.1%)	64 (39.0%)	52 (31.9%)	76 (45.8%)	45 (28.1%)	78 (46.4%)	38 (23.8%)	52 (32.1%)	35 (22.2%)	36 (22.2%)	26 (15.1%)	32 (18.2%)

N = Naproxen; C = Colchicine

* These are higher denominator numbers since questions on side-effects on day 7 were included in minimal data collection retrieval.

[#] Includes the side-effects listed and 'other' (nominated free-text) side-effects.

Supplementary table 5: Mean (SD) resource use, costs and outcomes per participant over 4 weeks follow-up

	Naproxen (n=200)	Colchicine (n=199)	Difference (CI)
RESOURCE USE			
GP visits	0.19 (0.34)	0.27 (0.40)	-0.08 (-0.15 to 0.0002)
Nurse visits	0.05 (0.19)	0.07 (0.22)	-0.02 (-0.06 to 0.03)
Emergency GP visits	0.05 (0.17)	0.04 (0.18)	0.01 (-0.03 to 0.04)
A and E visits	0.006 (0.07)	0.007 (0.07)	-0.001 (-0.02 to 0.01)
COSTS (£)			
Drug costs	0.83 (2.00)	1.20 (2.22)	-0.37 (-0.78 to 0.02)
GP costs	6.44 (11.16)	8.80 (13.16)	-2.36 (-4.74 to 0.12)
Nurse costs	0.66 (2.26)	0.86 (2.71)	-0.20 (-0.68 to 0.31)
Emergency GP costs	2.45 (8.54)	2.14 (8.68)	0.31 (-1.28 to 2.04)
A and E costs	0.41 (5.10)	0.48 (5.15)	-0.07 (-1.21 to 0.95)
Intervention cost	6.77 (4.56)	9.83 (6.32)	-3.06 (-4.17 to -2.08)
Total cost	17.57 (20.38)	23.31 (23.46)	-5.74 (-10.03 to -1.64)
HEALTH OUTCOMES			
Baseline EQ-5D	0.665 (0.21)	0.663 (0.22)	0.002 (-0.04 to 0.04)
Day 7 EQ-5D	0.882 (0.13)	0.873 (0.14)	0.009 (-0.02 to 0.03)
Week 4 EQ-5D	0.900 (0.11)	0.894 (0.15)	0.006 (-0.02 to 0.03)
QALYs	0.0663 (0.008)	0.0657 (0.01)	0.0006 (-0.001 to 0.002)
Adjusted QALYs ⁺	0.0662	0.0658	0.0004
WORK-RELATED OUTCOMES			
Time off work (days)	0.40 (2.47)	0.35 (2.51)	0.05 (-0.42 to 0.53)
Productivity cost (£)	32.16 (190.40)	28.44(207.42)	3.72 (-34.27 to 40.73)

⁺Adjusted for baseline EQ-5D